Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, and Cancer Immunotherapy and Biomarkers.
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance.
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).
Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma.
Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Evaluation of sex inequity in lung-cancer-specific survival.
Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway-A Nation-Wide Population Study.
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
Factors affecting outcome in resected <i>EGFR</i>-mutated lung cancer.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study.
Intracranial effect of osimertinib in relapsed <i>EGFR</i>-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Antibody combinations for optimized staining of macrophages in human lung tumours.
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives.
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases.
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer